We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Treatment of M.Graves With Radioactive Iodine: Follow-up Study

The recruitment status of this study is unknown. The completion date has passed and the status has not been verified in more than two years.
Verified May 2008 by Medisch Centrum Rijnmond-Zuid, Netherlands.
Recruitment status was:  Recruiting
Sponsor:
ClinicalTrials.gov Identifier:
NCT00525122
First Posted: September 5, 2007
Last Update Posted: May 22, 2008
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by:
Medisch Centrum Rijnmond-Zuid, Netherlands
  Purpose

Hypothesis: What is the natural course after treatment with radioactive iodine in patients with hyperthyroidism?

What are the determinants for the development of acute hypo- or hyperthyroidism after treatment with radioactive iodine without antithyroid drugs?


Condition
Hyperthyroidism

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Prospective

Resource links provided by NLM:


Further study details as provided by Medisch Centrum Rijnmond-Zuid, Netherlands:

Estimated Enrollment: 100
Study Start Date: September 2007
Groups/Cohorts
1
Patients with hyperthyroidism who are will be treated with radioactive iodine.

  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Patients of 18 years and older with hyperthyroidism who are eligible for treatment with radioactive iodine.
Criteria

Inclusion Criteria:

  • Patients wth hyperthyroidism who are eligible for treatment with radioactive iodine
  • Age > 18 years

Exclusion Criteria:

  • Severe ophthalmopathy
  • Pregnancy or wish to pregnancy on short term
  • Breastfeeding
  • Patients already treated with radioactive iodine
  • Known cardiovascular diseases or other severe comorbidity
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00525122


Contacts
Contact: A. Berghout, MD, PhD 0031 10 2913368 BerghoutA@mcrz.nl

Locations
Netherlands
MCRZ Recruiting
Rotterdam, Zuid-Holland, Netherlands, 3075 EA
Contact: A Berghout, MD, PhD         
Sponsors and Collaborators
Medisch Centrum Rijnmond-Zuid, Netherlands
Investigators
Principal Investigator: A. Berghout, MD, PhD Medisch Centrum Rijnmond-Zuid, Netherlands
Principal Investigator: C. van Noord, MD Medisch Centrum Rijnmond-Zuid, Netherlands
  More Information

Responsible Party: A. Berghout, MCRZ
ClinicalTrials.gov Identifier: NCT00525122     History of Changes
Other Study ID Numbers: 2006/60
First Submitted: September 4, 2007
First Posted: September 5, 2007
Last Update Posted: May 22, 2008
Last Verified: May 2008

Keywords provided by Medisch Centrum Rijnmond-Zuid, Netherlands:
hyperthyroidism
radioactive iodine
antithyroid drugs
Hyperthyroidism, treatment with radioactive iodine without antithyroid drugs

Additional relevant MeSH terms:
Hyperthyroidism
Thyroid Diseases
Endocrine System Diseases
Iodine
Antithyroid Agents
Anti-Infective Agents, Local
Anti-Infective Agents
Trace Elements
Micronutrients
Growth Substances
Physiological Effects of Drugs
Hormone Antagonists
Hormones, Hormone Substitutes, and Hormone Antagonists